CytomX Therapeutics (CTMX) EBITDA (2014 - 2026)

CytomX Therapeutics (CTMX) has 13 years of EBITDA data on file, last reported at -$19.7 million in Q1 2026.

• Quarterly EBITDA fell 186.96% year-over-year to -$19.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$64.7 million (down 279.81% YoY) and the FY2025 annual result came in at -$22.4 million, down 189.47% from the prior year.
• EBITDA rose to -$19.7 million in Q1 2026, from -$27.9 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $22.6 million in Q1 2025 to a low of -$32.1 million in Q1 2022.
• A 5-year average of -$7.3 million and a median of -$5.7 million in 2023 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2024 — EBITDA surged 3017.33% — and 2025, when it tumbled 483.56%.
• Tracing CTMX's EBITDA over 5 years: stood at -$9.5 million in 2022, then jumped by 93.63% to -$606000.0 in 2023, then surged by 3017.33% to $17.7 million in 2024, then slumped by 258.0% to -$27.9 million in 2025, then climbed by 29.57% to -$19.7 million in 2026.
• The last three EBITDA figures came in at -$19.7 million (Q1 2026), -$27.9 million (Q4 2025), and -$15.8 million (Q3 2025), per Business Quant data.